Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing …
431 Background: EV is an ADC that selectively targets and kills cells expressing Nectin-4 by
delivering a potent microtubule-disrupting agent, monomethyl auristatin E. As mUC tumors …
delivering a potent microtubule-disrupting agent, monomethyl auristatin E. As mUC tumors …
[HTML][HTML] Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
Background: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for patients
with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers …
with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers …
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma
AO Siefker-Radtke, D Cauley… - Journal of Clinical …, 2023 - ascopubs.org
Enfortumab vedotin (EV) with pembrolizumab has now joined gemcitabine carboplatin plus
maintenance avelumab as a frontline standard for cisplatin-ineligible patients with …
maintenance avelumab as a frontline standard for cisplatin-ineligible patients with …